Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care

Windree Therapeutics CEO and President Craig Fraser discusses the unmet needs in acute care, Windtree's pipeline, the importance of Fast Track designations, and how his past military career primed him for success as a pharma leader.

Craig Fraser

Craig was appointed Windtree’s President and Chief Executive Officer in February 2016 in addition to joining as a member of the Board of Directors. Craig brings more than 29 years of experience as a leader in product development and commercial operations and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining Windtree, Craig held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Novelion (AEGR) Therapeutics, Vice President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Craig is a veteran of both the U.S. Marine Corps and the U.S. Army.

Q: